Abstract Methods for assaying lysosomal diseases in dried blood samples are very useful today due to its several advantages related to the stability of samples, its transportation, handled and analysis, and its potential use for newborn screening compared to traditional methods in leucocytes samples. For this reason, it is important to validate these assays before being used in routine laboratory. Because of different in biological markers based on ethnicity, we aimed this study to validation a DBS-based fluorometric assay for measurement of a-L-Iduronidase activity for diagnosis of MPS I patients in Iran. DBS samples were collected from 15 MPS I patients and 60 healthy age matched subjects. Diagnostic value, biological variance and a-L-Iduronidase activity were determined. DBS a-L-Iduronidase activity was significantly higher in male subjects than in female group. Using a cut-off level of 1.08 lmol/spot 20 h, sensitivity and specificity were 100 and 98 %. The linearity of test was proved and we showed that within-run and between run precision were 5.6 and 14.66 %. Measurement of a-L-Iduronidase activity in DBS samples is an accurate test for diagnosis of MPS I and because of its rapid shipping and simplicity to keeping, DBS-based enzyme activity could be considered as a useful diagnostic tool in this disease.
Introduction
Mucopolysaccharidosis type I is a family member of lysosomal storage diseases which is characterized by skeletal deformities (dysostosis multiplex), coarse facial features, hepatosplenomegaly, an enlarged head, cardiomyopathy, hearing loss, macroglossia, and respiratory tract infections [1] . The main cause of this genetic disorder is decrease and/or lack of a-L-Iduronidase (EC.3.2.1.76) activity (an enzyme responsible for the degradation of mucopolysaccharides in lysosomes) that result in glycoseaminoglycans accumulation in cell and cause tissue damage [1, 2] . MPS I patients may show three clinical manifestations: MPS I H or Hurler syndrome is the most severe of the MPS I subtypes. The other two types are the mild form MPS I S or Scheie syndrome and the moderate form MPS I H-S or Hurler-Scheie syndrome [1] . Laboratory diagnosis of MPS I is based on determination of concentration and the type of secreted GAGs from urine, measurement of enzyme activity and finally definition of mutation type [2, 3] . The gold standard for the diagnosis of MPS I is measurement of a-L-Iduronidase activity at acidic pH in leukocyte or fibroblast homogenates of patients [1, 3] . Serum or plasma samples may also be used when enzyme activity in those materials is sufficiently high [1, 4] . One of the major limitations in rapid measurement of enzyme activity is providing the high quality samples and shipping samples to laboratory. More recently, use of dried blood spots (DBS) for determination of a-L-Iduronidase activity has been reported [2] . According to availability of DBS samples, development of DBS-based enzyme activity measurement is highly desirable. Enzyme activity can be determined by methods such as fluorometric assay, radioactive labeled substrates, Immunocapture and mass spectrometry [1, [5] [6] [7] [8] . Because of novelty of method, there is little research on method validation, hence, for the first time in Iran we aimed this study to evaluate the validity of fluorometric assay of a-L-Iduronidase activity in DBS samples for diagnosis of MPS I.
Materials and Methods

Study Subjects
In this study, DBS samples from sixty healthy male and female subjects in the age range of 1 month to 45 years were evaluated. Subjects who show any clinical evidence of chronic diseases and other genetic disorders were excluded from study. Moreover, for determination of the diagnostic criteria's, a group comprised of fifteen MPS I patients were enrolled in the study. Blood samples were taken before treatment. DBS samples were prepared on Whatmans 
Fluorometric Assay
The method was a modification of that described by Chamoles et al. [2] . Briefly, one 3-mm spot is punched from dried blood on filter paper and placed into 1.5 ml microtube. Then 20 ll of 2 mM 4-methylumbelliferyl-a-L-(idopyranosid)-uronic acid sodium salt, 20 ll of 10 mM Dsaccharic acid-1,4-lactone buffer and 110 ll of incubation buffer (pH 3.5) comprised of phosphate buffer 0.2 M and citric acid solution 0.1 M were added to each sample. The microtubes were sealed with tape, covered with aluminum wrapping and incubated at 37°C for 20 h. After incubation, the assay is stopped with 200 ll stop solution/glycinecarbonate buffer (pH 9.6). Blanks were treated as described above but the substrate solution was added after 20 h incubation and just before the addition of stop solution. Finally, 250 ll of each samples was poured into a 96-well microtiter plates and fluorescence was read with an excitation wave-length of 365 nm and an emission wavelength of 450 nm by fluorescence microplate reader (BioTek Instruments, Inc, Winooski, United States). All tests were performed in duplicate. Results were calculated from the calibration curve after adjusting for the blank. Results were expressed as lmol/spotÁincubation time. A calibration curve was prepared using different dilutions of 4-MU standards (0-500 lmol/l).
Low range results were confirmed by leukocyte assay. The assay was based on the method designated by Stirling et al. [9, 10] . After preparation a calibration curve and blanks, for each patient sample, 10 ll of leukocyte homogenate was moved to separate wells on the microtiter plate. Then 20 ll of inhibition buffer as well as 20 ll of substrate buffer were added and the volume was adjusted to 200 ll using the reaction buffer. The plate is closed with tape and protected in aluminum wrapping. It was incubated at 37°C for 20 h. The reaction was stopped with 200 ll stop solution. The plate is shaken briefly and read with an excitation wavelength of 365 nm and an emission wave length of 450 nm.
Statistical Analysis
Data presented as mean ± SD and analyzed by SPSS 16 (SPSS Inc., Chicago, USA) and independent samples T test used to compare mean differences. Moreover, one-way ANOVA followed by PostHoc, Tukey and Dunnet tests was used to analyze differences between groups and the p value less than 0.05 was considered as significant. Cutoff values that provided the best combination of sensitivity and specificity were determined by receiver operating characteristic (ROC) curves curve analysis. Sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio were calculated. To estimate precision, within-run and between-run coefficient of variance (CV%) were analyzed using control samples. Within-run CV% was calculated on ten replicates of each control. Between-run CV% was estimated by analysis of five replicates per day on five consecutive days. Accuracy was assessed in three DBS samples obtained by mixing equal proportions of compatible whole blood with known enzyme activity controls (high, medium and low activity). In addition, the evaluation of the inter-individual variability (among individuals) and intra-individual variability (within the same individual when repeatedly measured) of the enzyme activity measurement was assessed by comparing data from the subset of DBS samples which were tested three times (n = 15) [11] [12] [13] .
Results Figure 1 shows the IDUA activity in DBS samples from patients and control groups. Mean concentration of enzyme activity was 0.17 ± 0.34 lmol/spot 20 h in patients group (ranged between 0.01 and 1.08 lmol/spot 20 h) and 9.37 ± 11.73 lmol/spot 20 h healthy subjects (ranged between 1.14 and 58.1 lmol/spot 20 h) (p \ 0.0001). The samples were divided into two groups based on gender of subjects. The results show that enzyme activity tended to increase in male group than females, even though it was not significant (Table 1 ; Fig. 2 ). Enzyme activity in DBS samples were 7.04 ± 9.78 lmol/spot 20 h for male group and 6.82 ± 12.82 lmol/spot 20 h for female subjects. Furthermore, according to age of subjects, samples were divided into three age range (R1 \ 84 month, R2: 84-180 month and R3 [ 180 month). Data analysis also confirmed that a-L-Iduronidase activity significantly (p = 0.0026) differs in DBS samples from R3 subclasses of age range classification and R3 sample populations tends ROC curve analysis revealed that cut-off level is 1.08 lmol/spot 20 h for enzyme activity in DBS sample. Using this cut-off level for DBS a-L-Iduronidase activity, sensitivity and specificity were 100 and 98 %, respectively. Besides, according to obtained sensitivity and specificity, positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio were evaluated ( Table 2) .
The validation criteria's reflected the activity of enzyme in DBS samples in that the low control had the lowest activity, the high control had the highest activity, and the medium control were intermediate (0.31, 2.94 and 9.94 lmol/spot 20 h for low, medium and high control respectively). Within and between run CV% were 5.6 and 14.66 %, respectively. The obtained analytical variation by combination of withinrun and between-run measurements was 10.13 %.
The sources of biological variation divided into inter individual variance (CV I ) and intra individual variance (CV G ) ( Table 2 ). For enzyme assay using DBS samples, the main variance was attributed to intra individual variability, indicating that the majority of difference with in our study population was due to differences among individuals. We hypothesize that the physiological characteristics of individuals is the major contributor to this variability.
For optimal test interpretation, the analytical acceptability index specifies having CV A B 1/2 CV I or CV A / CV I B 0.5 [14] . The described assays had an analytical acceptability index less than 0.5.
Conclusion
In this study we setup and validated the a-L-Iduronidase activity test in DBS samples for the first time in Iran. Evaluations of lysosomal enzymes are tests which are performed in specialized laboratories. In many countries, especially in low-income countries, there is not possible to perform these tests in all provinces, so a reference laboratory assumes performing these tests. Hence, using of DBS samples which can be rapidly shipping by mail is very desirable [15, 16] . The quality of DBS samples directly effects on obtained results [17] . Discolored, overloaded, or insufficient samples may lead to inaccurate outcomes [1] .
Measurement of a-L-Iduronidase enzyme activity is the final step in MPS I diagnosis [1] . Many biological samples such as serum, plasma, leukocytes, fibroblasts and more recently DBS have been used for determination of enzyme activity. According to novelty of DBS-based enzyme activity measurement method, little study has been done in this area. Muller et al. [18] in Brazil proved that measurement of a-L-Iduronidase activity in DBS samples is an accurate tool for diagnosis of MPS I patients. However they strongly recommended that only high quality samples should be used for this test. To obtain the highest sensitivity and specificity they used a cut-off level of 1.5 lmol/l blood/h. They showed that in healthy Brazilian population, age ranged between 18 until 73 years, a-L-Iduronidase activity in DBS were ranged from 1.4 to 7.78 lmol/l blood/ h. Besides, based on their study the within-run and between run CV percent was ranged 4.7-5.6 % and 18.6-19.3 %, respectively. They have mentioned that the highest enzyme activity in their MPS I groups was 1.09 lmol/l blood/h [18, 19] . More recently, Campos et al. [20] standardized enzymatic measurement of a-L-Iduronidase activity in DBS samples in a Cuban population. a-L-Iduronidase activity in DBS samples were 10.93, 12.21, 0.29 and 7.89 lmol/l blood/h for healthy adults, healthy neonates, MPS I Fig. 3 Difference between study subjects according to age LR likelihood ratio, PPV positive predictive value, NPV negative predictive value, CV W % within-run CV%, CV B % between-run CV%, CV A % analytical variance, CV I % inter individual variance, CV G % intera individual variance patients and heterozygote subjects. Among the other studies, it is the highest activity that reported for a-L-Iduronidase in DBS samples. They showed that this increase of activity was given by precipitation of hemoglobin and using DBS matrix for plotting standard curve. Within-run CV% for low, medium and high a-L-Iduronidase activity in DBS samples were 9.23, 7.75 and 7.04 %, respectively, while between run CV% were 9.32,7.86 and 7.76 %, respectively. Limit of detection with a probability of 95 %, was 0.10 lmol/l blood/h. In our study, using cut-off level of 1.08 lmol/spot 20 h sensitivity and negative predictive value were 100 %. Furthermore, biological variance which obtained by our study such as within-run CV%, between run CV%, inter individual CV% and analytical CV% are considerably differing from other study. This alteration could be due to procedure used for determination of enzyme activity. In the present study we used citric acid solution and phosphate buffer as incubation buffer. In addition, the mean activity of a-L-Iduronidase activity in DBS samples in our study were 9.37 ± 11.73 lmol/spot 20 h for healthy groups and 0.17 ± 0.34 lmol/spot 20 h for MPS I patients. Comparison of these results with other data obtained by other studies revealed that there is a significant difference between enzyme activity in different population. This alteration could be due to sampling and/or patient selection. Furthermore, we compared the studied subjects based on age range and gender. These finding showed in addition to enzyme activity by age range, there is a tendency to increase in a-L-Iduronidase activity in male group than female. The advantage of present study was using age matched control group. We determine enzyme activity in 1 month until 15 years old healthy subjects. Given that the age of onset of the disease in all three forms is less than 15 years, use the controls in the same range is much better.
The obtained analytical parameters demonstrate that the method is readily applicable to diagnosis MPS I. The method has been found to be reliable, but it is essential to highlight that laboratory assay results should always be analyzed together with other information as clinical symptoms and familial history.
